Stock · BAX · Healthcare
United States · Large Cap · listed since 1981 · Revenue 12 mo. $11.6B
Price as of 11/06/2026
Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States.
Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. It offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; inhaled anesthetics; generic injectable pharmaceuticals; surgical hemostat and sealant products; advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space comprising operating room integration technologies, precision positioning devices, and other accessories. The company also provides specialty injectable pharmaceuticals, inhaled anesthetics, and drug compounding services. Its products are used in hospitals, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, kidney dialysis centers, and patients at home under physician supervision. The company sells its products through direct sales force, independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers. It operates in Eastern Europe, the Middle East, Africa, Latin America, Asia, Western Europe, Canada, Japan, Australia, and New Zealand. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.
Original text from the data provider
Summary
32.4 of 100
Mean of the six area values. Each area value is the mean of the stock's ranks among the companies in its sector. 50 is the middle of the sector, not a share of companies beaten.
Analysis
What the price requires
If free cash flow stays at €289.9M (2025), it supports €3.2B. The remaining €8.7B of the market value assume it grows 18.2% a year for 10 years and not at all afterwards.
Required FCF growth per year
18.2%
no growth afterwards
Price to operating cash flow 8.2×, below its usual range.
Middle half of 20 quarters: 11.7× to 18.7×, median 15.1×.
Measures only against its own past, not against what the company is worth. Price as of 11/06/2026.
with respect to the priced-in expectation
with respect to the priced-in expectation
Since the last quarter
Q2 → Q3 2026
5 more unchanged: Revenue, 12 mo., Gross margin, EBIT margin, Net debt, Shares outstanding
Derivation
Each area value is the average of its metrics' ranks within the sector (0 to 100, 50 is the middle). For metrics where lower is better, the rank is mirrored. The overall value is the average of the area values.
Price as of 11/06/2026.
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Return on equity | −15.61% | 11.52% | Rank 8 |
| Return on capital (Greenblatt) | −4.35% | 32.55% | Rank 7 |
| EBIT margin | −2.74% | 18.31% | Rank 5 |
| FCF margin | 2.87% | 14.12% | Rank 13 |
| Gross margin | 30.05% | 60.99% | Rank 17 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Revenue growth, 1 year | 5.72% | 8.04% | Rank 38 |
| Earnings growth, 3 years per yeardoes not count towards the rank | – | 5.44% | |
| Earnings growth, 5 years per yeardoes not count towards the rank | – | 7.00% | |
| Sustainable growth (ROE × retained earnings) | 4.64% | 3.66% | Rank 57 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Earnings yield | −7.23% | 2.90% | Rank 1 |
| FCF yield | 2.44% | 3.63% | Rank 30 |
| EV/saleslower is better | 1.89 | 4.03 | Rank 80 |
| EV/EBITlower is betterdoes not count towards the rank | – | 21.73 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Share price, 1 year | 33.83% | 8.66% | Rank 79 |
| Share price, 6 months | 43.84% | 24.27% | Rank 81 |
| Share price, 3 months | −1.26% | 15.42% | Rank 12 |
| Distance from 52-week high | −9.03% | −7.35% | Rank 43 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Accruals (Sloan)lower is better | −20.26% | 0.30% | Rank 98 |
| Change in share countlower is better | 0.59% | 0.00% | Rank 19 |
| Dividend streak in years | 0 | 10 | Rank 13 |
| Price reaction to results, market-adjusted | −7.65% | 0.05% | Rank 4 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Equity ratio | 30.56% | 48.40% | Rank 20 |
| Net debt/EBITDAlower is better | 10.49 | 1.11 | Rank 1 |
| Debt to equitylower is better | 1.63 | 0.48 | Rank 10 |
| Volatility, 1 yearlower is better | 42.15% | 31.42% | Rank 20 |
Ten years in figures
| Year | Revenue, $B | EBIT margin | FCF | Shares | Net debt |
|---|---|---|---|---|---|
| 2016 | 10.2 | 7.3% | $935.0M | 551M | −$19.0M |
| 2017 | 10.6 | 12.2% | $1.1B | 555M | $118.0M |
| 2018 | 11.1 | 14.3% | $1.4B | 546M | $1.6B |
| 2019 | 11.4 | 15.6% | $1.4B | 519M | $2.6B |
| 2020 | 11.7 | 13.8% | $1.2B | 517M | $3.1B |
| 2021 | 12.1 | 11.1% | $1.5B | 508M | $15.4B |
| 2022 | 10.1 | −28.3% | $532.0M | 504M | $15.5B |
| 2023 | 10.4 | 6.8% | $1.3B | 506M | $11.0B |
| 2024 | 10.6 | 0.1% | $559.0M | 510M | $11.7B |
| 2025 | 11.2 | −2.7% | $323.0M | 513M | $8.0B |
1 of 7 StockScorer Score rules met · How the score is built
Baxter International Inc mainly meets criteria in the Momentum category. Result from 18 strategies checked.
Baxter International Inc is rated here with the StockScorer Score strategy, the flagship rule set. It compares return and cash-flow metrics with the median of the company's own sector and checks growth and price trend.
1 of 7 rules met
1 of 11 points
Detail data
Excerpt from 18 strategies checked. The full evaluation is visible after a free sign-up.
With a free account, you can see the match across all strategies checked in one complete overview.
Selected fundamental metrics for Baxter International Inc.
| Metric | Stock | Sector |
|---|---|---|
| P/E ratio | −11.9 | 30.0 |
| P/B ratio | 2.2 | 4.8 |
| Return on equity (ROE) | −15.6% | 11.5% |
| Equity ratio | 30.6% | 48.4% |
| Debt-to-equity (D/E) | 1.63 | 0.48 |
| Dividend yield | 0.2% | 1.3% |
How comparable stocks in the same sector score in the StockScorer model.
| Symbol | Company | Rating |
|---|---|---|
| BAX | Baxter International Incthis page | |
| RGEN | Repligen Corporation | locked |
| COO | The Cooper Companies, Inc | Low1.8 |
| ALGN | Align Technology Inc | Low1.8 |
| SOLV | Solventum Corp. | locked |
| WST | West Pharmaceutical Services Inc | locked |
Signed up in 30 seconds, free.
Learn more about the metrics in the metrics glossary or all rated stocks in the stock overview.
How StockScorer rates every stock is explained on the methodology page.